Close Menu
Home » FDA Clears NantHealth Tumor-Normal Whole-Exome Test

FDA Clears NantHealth Tumor-Normal Whole-Exome Test

Nov 12, 2019
|
staff reporter

NEW YORK – The US Food and Drug Administration has granted 510(k) clearance to NantHealth for its Omics Core technology, a whole-exome tumor-normal in vitro diagnostic that measures overall tumor mutational burden in cancer tissue and reports somatic mutations in 468 cancer-relevant genes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

GEDmatch Under New Owners

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Generations of Bunnies

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

To Inform the Discussion

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

PNAS Studies on ER+ Breast Cancer Target, Skin Condition Gene Repair, Uveoretinitis

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.